J. Coyle et P. Kershaw, Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease, BIOL PSYCHI, 49(3), 2001, pp. 289-299
Despite the proven efficacy of acetylcholinesterase inhibitors in Alzheimer
's disease, there is a need for new and more effective treatments. Galantam
ine is a novel treatment for Alzheimer's disease that inhibits acetylcholin
esterase and modulates nicotinic receptors. In randomized, double-blind, pl
acebo-controlled studies of up to 6 months duration, galantamine significan
tly improved cognitive function. Galantamine also had beneficial effects on
instrumental and basic activities of daily living, and postponed the progr
ession of behavioral symptoms. Patients who completed one of the 6-month, p
lacebo-controlled studies were eligible to enter a 6-month, open-extension
study of 24-mg/day dose of galantamine. At the end of 12 months, cognitive
function and activities of daily living were preserved in those patients wh
o had been treated throughout the study with galantamine 24 mg/day. At 12 m
onths, this group of patients had significantly better cognitive functions
than patients who had been treated with a placebo for 6 months before recei
ving galantamine. These studies indicate that galantamine postpones the pro
gression of symptoms in Alzheimer's disease. Since galantamine shows the gr
eatest benefits when treatment is started early, its long-term benefits may
result from an effect on the underlying disease process; such an effect mi
ght be mediated by galantamine's concomitant action on nicotinic receptors.
(C) 2001 Society of Biological Psychiatry.